Used in pharmaceutical research as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), this compound is being investigated for the treatment of autoimmune diseases and certain B-cell malignancies. It modulates B-cell receptor signaling, leading to reduced activation, proliferation, and survival of malignant or autoreactive B cells. Due to its high selectivity and irreversible binding to BTK, it shows promise in conditions such as rheumatoid arthritis, chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). Its structure enables improved pharmacokinetic properties, including oral bioavailability and sustained target inhibition, making it suitable for once-daily dosing in clinical settings.